SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a promising therapy for diabetes and CKD patients. However, the pros and cons of SGLT2i in Type2 diabetes patients with CKD stage 5 remained largely unexplored. By using Taiwan’s national health insurance research database (N...

Full description

Saved in:
Bibliographic Details
Main Authors: Birdie Huang, Chieh-Li Yen, Chao-Yi Wu, Chung-Ying Tsai, Jia-Jin Chen, Ching-Chung Hsiao, Yung-Chang Chen, I-Chang Hsieh, Huang-Yu Yang
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
CKD
Diabetes
ESRD
MACCE
SGLT2 inhibitor
Online Access:https://doi.org/10.1038/s41598-024-81973-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-81973-z

Similar Items